MANKIND — Mankind Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Mankind Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	C2022 March 31st	2023 March 31st	R2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	77,816	87,494	102,604	122,074	142,776
Cost of Revenue
Gross Profit	52,084	56,781	68,780	84,888	102,255
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	59,296	71,747	81,234	96,386	116,762
Operating Profit	18,520	15,747	21,371	25,688	26,015
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	19,746	16,712	23,979	25,163	23,327
Provision for Income Taxes
Net Income After Taxes	14,530	13,097	19,408	20,066	19,381
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	14,335	12,819	19,129	19,910	19,129
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14,335	12,819	19,129	19,910	19,129
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	35.4	32.1	47.6	45.8	48.9